Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
Atypical sarcoidosis diagnosed by bone marrow biopsy during renal workup for possible multiple myeloma | SpringerLink
The Diagnostic Value of Kappa/Lambda Ratios Determined by Immunohistochemistry in the Differentiation of Plasma Cell Myeloma fro
Familial Myeloma | NEJM
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials | PLOS ONE
Monoclonal gammopathy of renal significance: Early diagnosis is key | Nefrología
Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease | PLOS ONE
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels | Haematologica
SciELO - Brasil - Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies Serum free light chain assays not total light chain
Serum Free Light Chains
Manni Mohyuddin on Twitter: "Thus in normal situations, kappa/lambda ratio is actually usually slightly less than 1, since lambda sticks around in blood more than kappa." / Twitter
free light chains ratio in AL amyloidosis, kappa and lambdaAmyloidosis Patient Information Site
Multiple Myeloma 101: Understanding Your Labs
Page 1 of 9 Title: Flow Cytometric Testing for Kappa and Lambda light chains Sponsored and reviewed by ICCS Quality and Standar
Understanding Freelite®, the lab test for serum free light chains
Multiple myeloma: Diagnosis and management issues in patients with pre-existing chronic kidney disease